

## Icaritin Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)

### [ Product Information ]

**Name:** Icaritin


**Catalog No.:** CFN98527

**Cas No.:** 118525-40-9

**Purity:** >=98%

**M.F:** C<sub>21</sub>H<sub>20</sub>O<sub>6</sub>

**M.W:** 368.38



**Physical Description:** Yellow powder

**Synonyms:** 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; 3,7-bis(2-hydroxyethyl)icaritin.

### [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

### [ Source ]

The roots of *Epimedium brevicornu Maxim.*

### [ Biological Activity or Inhibitors ]

Icariin, a principal flavonoid glycoside in *Herba Epimedii*, it can enhance the differentiation and proliferation of osteoblasts, and facilitate matrix calcification; meanwhile it inhibits osteoclastic differentiation in both osteoblast–preosteoclast coculture and osteoclast progenitor cell culture, and reduces the motility and bone resorption activity of isolated osteoclasts.<sup>[1]</sup>

Icaritin and desmethylicaritin are novel phytoestrogens and that the estrogenic effects of icaritin and desmethylicaritin are mediated by the estrogen receptor, they have proliferation-stimulating effects in MCF-7 cells.<sup>[2]</sup>

Icariin has promoting effect on cardiac differentiation, which is related to increasing and accelerating gene expression of  $\alpha$ -cardiac MHC and MLC-2v, as well as regulating the cell cycles and inducing apoptosis. <sup>[3]</sup>

Icaritin has osteoprotective potential, exerts dose-dependent effect on reducing incidence of steroid-associated ON with inhibition of both intravascular thrombosis and extravascular lipid-deposition; suppression of the up-regulated PPARgamma expression for extravascular adipogenesis of mesenchymal stem cells and protection from activated oxidative stress for intravascular endothelium injury are found to be involved in the underlying mechanisms.<sup>[4]</sup>

Icaritin has a novel anticancer efficacy, which mediated selectively via induction of cell cycle arrest but not associated with estrogen receptors in PC-3 cells.<sup>[5]</sup>

Icaritin has neuroprotective effect against the toxicity induced with A $\beta$  25-35 in primary cultured rat cortical neuronal cells, mitogen-activated protein kinase/extracellular signal-regulated kinase pathway may be involved in and partly contributed to the neuroprotective effects of icaritin.<sup>[6]</sup>

Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.<sup>[7]</sup>

## **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

## **[ HPLC Method ]<sup>[8]</sup>**

Mobile phase: Methanol -H<sub>2</sub>O=82:18 ;

Flow rate: 1.0 ml/min;

Column temperature: 30 °C;

The wave length of determination: 270 nm.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

- [1] Huang J, Yuan L, Wang X, *et al. Life Sci.*, 2007, 81(10):832-40.
- [2] Wang Z Q, Lou Y J. *Eur.J.Pharmacol.*, 2004, 504(3):147-53.
- [3] Zhu D Y, Lou Y J. *Acta Pharmacol. Sin.*, 2005, 26(4):477-85.
- [4] Zhang G, Qin L, Sheng H, *et al. Bone*, 2009, 44(2):345-56.
- [5] Huang X, Zhu D, Lou Y. *Eur. J. Pharmacol.*, 2007, 564(1-3):26-36.
- [6] Wang Z, Zhang X, Wang H, *et al. Neuroscience*, 2007, 145(3):911-22.
- [7] Zhu J F, Li Z J, Zhang G S, *et al. Plos One*, 2011, 6(8):e23720-e23720.
- [8] Jia D S, Jia X B, Shi F, *et al. Journal of Chinese Pharmaceutical Sciences*, 2010, 45(5):353-8.

## **[ Contact ]**

### **Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)